{
    "eid": "2-s2.0-85100608446",
    "title": "Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis",
    "cover-date": "2021-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Evidence map",
        "NASH",
        "Systematic review",
        "Treatment"
    ],
    "authors": [
        "Chanthawat Patikorn",
        "Sajesh K. Veettil",
        "Pochamana Phisalprapa",
        "Tuan Pham",
        "Kris V. Kowdley",
        "Nathorn Chaiyakunapruk"
    ],
    "citedby-count": 3,
    "ref-count": 61,
    "ref-list": [
        "Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?",
        "Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes",
        "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States",
        "Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis",
        "Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis",
        "Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map",
        "Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence MAP",
        "Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD",
        "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial",
        "Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study",
        "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study",
        "Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial",
        "The panPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic nash: results of the NATIVE phase 2b trial",
        "Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis",
        "A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis",
        "Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis",
        "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial",
        "Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis",
        "The role of thiazolidinediones in non-alcoholic steatohepatitis \u2014 a systematic review and meta analysis",
        "Imm-124E improves metabolic endotoxemia and markers of liver injury in nonalcoholic steatohepatitis",
        "Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot",
        "NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial",
        "Final analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter study of aldaferMIN (NGM282) in patients with nonalcoholic steatohepatitis",
        "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial",
        "Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis",
        "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study",
        "Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial",
        "Novel, first-in-class, fatty acid synthase (FASN) inhibitor, TVB-2640 demonstrates clinically significant reduction in liver fat by mri-pdff, and alt in nash: a phase 2 randomized placebo-controlled trial (FASCINATE-1)",
        "Efruxifermin (EFX), a long-acting FC-FGF21 fusion protein, administered for 16 weeks to patients with nash substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, phase 2a study (BALANCED)",
        "AS078-EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study",
        "MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study",
        "Nidufexor, a non-bile acid FXR agonist, decreases ALT and hepatic fat fraction in patients with NASH after 12 weeks dosing",
        "Comparative analysis of efficiency of ursodeoxycholic acid and combination of vitamin E and vitamin C in treatment of non-diabetic nonalcoholic steatohepatitis",
        "Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from part C of the phase 2 flight-FXR study",
        "Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial",
        "Effects of dietary intervention on gut microbiota and metabolic-nutritional profile of outpatients with non-alcoholic steatohepatitis: a randomized clinical trial",
        "GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease",
        "Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial",
        "Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial",
        "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD",
        "A multipurpose nuclear receptor",
        "FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats",
        "Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease",
        "Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence",
        "Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease",
        "Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats",
        "Farnesoid X receptor antagonizes nuclear factor \u03baB in hepatic inflammatory response",
        "Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis",
        "Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet",
        "Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase",
        "Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis",
        "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis",
        "Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists",
        "VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat in patients with non-alcoholic fatty liver disease: a phase 2 randomized, placebo-controlled trial",
        "Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1/\u03b3/\u03b4 triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate",
        "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening",
        "Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis",
        "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials",
        "The natural course of non-alcoholic fatty liver disease",
        "Role of liver biopsy in nonalcoholic fatty liver disease",
        "Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Salt Lake City",
            "@id": "60025488",
            "affilname": "The University of Utah",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025488",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pullman",
            "@id": "60018208",
            "affilname": "Washington State University Pullman",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018208",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60011189",
            "affilname": "Faculty of Medicine Siriraj Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}